

The Evaluation Advisory Committee (EAC) Report

Quality assessment of the evaluation

Name of evaluation: Endline evaluation of Gavi's pilot Advanced Market Commitment (AMC) for Pneumococcal Conjugate Vaccine (PCV).

Year of report: 2021

a) The Evaluation Advisory Committee (EAC) rated this report as;

- Fully met or exceeded Gavi quality standards
- Met Gavi quality standards with only minor shortcomings
- Partially met Gavi quality standards with some shortcomings
- Did not meet Gavi quality standards with major shortcomings

b) General comments:

Strengths

The report is well written and well structured report. It is accessible to target users. The Purpose, scope and objectives well outlined. The methodological approach is clear and well described and the limitations are justified. The findings are drawn from a robust analysis and are based on evidence. The conclusions and recommendations are clear and logical.

Shortcomings

Little attention is given to country perspectives and contexts that could have influenced the PCV AMC implementation. The evaluation could have benefitted if many more country level respondents and policy makers especially ministers of finance were among those interviewed.